MX2020013633A - Metodos para producir proteinas recombinantes. - Google Patents

Metodos para producir proteinas recombinantes.

Info

Publication number
MX2020013633A
MX2020013633A MX2020013633A MX2020013633A MX2020013633A MX 2020013633 A MX2020013633 A MX 2020013633A MX 2020013633 A MX2020013633 A MX 2020013633A MX 2020013633 A MX2020013633 A MX 2020013633A MX 2020013633 A MX2020013633 A MX 2020013633A
Authority
MX
Mexico
Prior art keywords
cells
culturing
interest
perfusion
recombinant polypeptide
Prior art date
Application number
MX2020013633A
Other languages
English (en)
Spanish (es)
Inventor
Jianlin Xu
Andrew Yongky
Jun Tian
Michael C Borys
Zhengjian Li
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020013633(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020013633A publication Critical patent/MX2020013633A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020013633A 2018-07-03 2019-07-02 Metodos para producir proteinas recombinantes. MX2020013633A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862693606P 2018-07-03 2018-07-03
PCT/US2019/040298 WO2020010080A1 (en) 2018-07-03 2019-07-02 Methods of producing recombinant proteins

Publications (1)

Publication Number Publication Date
MX2020013633A true MX2020013633A (es) 2021-03-25

Family

ID=67470657

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013633A MX2020013633A (es) 2018-07-03 2019-07-02 Metodos para producir proteinas recombinantes.

Country Status (23)

Country Link
US (2) US12624336B2 (cg-RX-API-DMAC7.html)
EP (2) EP4368699A3 (cg-RX-API-DMAC7.html)
JP (3) JP7419273B2 (cg-RX-API-DMAC7.html)
KR (2) KR102870511B1 (cg-RX-API-DMAC7.html)
CN (1) CN112839954A (cg-RX-API-DMAC7.html)
AU (1) AU2019299358B2 (cg-RX-API-DMAC7.html)
CA (1) CA3104684A1 (cg-RX-API-DMAC7.html)
DK (1) DK3818078T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092904A1 (cg-RX-API-DMAC7.html)
ES (1) ES2976708T3 (cg-RX-API-DMAC7.html)
FI (1) FI3818078T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240584T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066560T2 (cg-RX-API-DMAC7.html)
IL (2) IL279782B2 (cg-RX-API-DMAC7.html)
LT (1) LT3818078T (cg-RX-API-DMAC7.html)
MX (1) MX2020013633A (cg-RX-API-DMAC7.html)
PL (1) PL3818078T3 (cg-RX-API-DMAC7.html)
PT (1) PT3818078T (cg-RX-API-DMAC7.html)
RS (1) RS65472B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012582QA (cg-RX-API-DMAC7.html)
SI (1) SI3818078T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400173T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020010080A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279782B2 (en) 2018-07-03 2026-05-01 Bristol Myers Squibb Co Methods for producing recombinant proteins
EP4229174A1 (en) * 2020-10-13 2023-08-23 Boehringer Ingelheim International GmbH Systems and methods for producing a biologic molecule with hydrocyclone cell retention device
DK181991B1 (en) * 2021-11-11 2025-05-15 Dsm Ip Assets Bv Combined fermentation process for producing one or more human milk oligosaccharide(s) (hmo(s)) in escherichia coli
AU2023295808A1 (en) * 2022-06-15 2025-01-30 UCB Biopharma SRL Cell culture processes
EP4339274B1 (en) 2022-09-13 2025-03-26 Sartorius Stedim Biotech GmbH Method for operating a bioprocess installation for production of a bioproduct
KR20240172522A (ko) * 2023-06-01 2024-12-10 (주)알테오젠 지속형 호르몬 수용체 길항제의 생산 방법

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP2749167B2 (ja) 1988-06-21 1998-05-13 ジェネンテク,インコーポレイテッド 心筋梗塞の処置のための方法および治療用組成物
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
EP1260521B1 (en) 1991-08-14 2007-11-21 Genentech Inc. Immunoglobulin variants for specific Fc epsilon receptors
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0733207B1 (en) 1993-12-10 1997-08-27 Genentech, Inc. Methods for diagnosis of allergy and screening of anti-allergy therapeutics
AP660A (en) 1994-01-18 1998-08-18 Genentech Inc A method of treatment of parasitic infection using IgE antagonists.
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
PT877626E (pt) 1996-01-23 2003-01-31 Univ Vermont And State Agric C Anticorpos anti-cd1s para utilizacao contra icto
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
AU731817C (en) 1996-11-27 2001-11-01 Genentech Inc. Humanized anti-CD11a antibodies
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
PT981618E (pt) 1997-05-15 2007-11-23 Genentech Inc ''anticorpo anti-apo-2''
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
KR100490077B1 (ko) 1999-10-29 2005-05-17 제넨테크, 인크. 항-전립선 줄기세포 항원 (psca) 항체 조성물 및 그의사용 방법
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
MX2009004974A (es) 2006-11-08 2009-05-20 Wyeth Corp Medios diseñado racionalmente para cultivo celular.
WO2009023562A2 (en) 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
DK2501822T3 (da) 2009-11-17 2017-11-27 Squibb & Sons Llc Fremgangsmåder til forbedret proteinproduktion
LT2673296T (lt) 2011-02-07 2019-02-25 Cerenis Therapeutics Holding Sa Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
SI2726600T1 (sl) * 2011-07-01 2017-07-31 Amgen Inc. Sesalska celična kultura
WO2015095809A1 (en) * 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
MA40021A (fr) * 2014-06-03 2015-12-10 Lupin Ltd Processus de culture cellulaire destiné à produire une protéine
KR102391259B1 (ko) * 2014-06-04 2022-04-26 암젠 인크 포유류 세포 배양물을 회수하는 방법
JP5731726B1 (ja) 2014-06-26 2015-06-10 楽天株式会社 情報処理装置、情報処理方法及び情報処理プログラム
EP3420072B1 (en) 2016-02-22 2025-06-18 Agency for Science, Technology and Research Cell culture medium
EP3440190B1 (en) 2016-04-05 2024-08-28 Pfizer Inc. Cell culture process
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
IL279782B2 (en) 2018-07-03 2026-05-01 Bristol Myers Squibb Co Methods for producing recombinant proteins

Also Published As

Publication number Publication date
PL3818078T3 (pl) 2024-04-29
RS65472B1 (sr) 2024-05-31
HUE066560T2 (hu) 2024-08-28
WO2020010080A1 (en) 2020-01-09
SMT202400173T1 (it) 2024-07-09
JP2024050590A (ja) 2024-04-10
EP3818078B1 (en) 2024-02-28
US12624336B2 (en) 2026-05-12
KR102870511B1 (ko) 2025-10-15
US20250171732A1 (en) 2025-05-29
US20210253996A1 (en) 2021-08-19
CN112839954A (zh) 2021-05-25
IL279782B2 (en) 2026-05-01
KR20210027427A (ko) 2021-03-10
LT3818078T (lt) 2024-04-25
EP4368699A3 (en) 2024-09-11
AU2019299358A1 (en) 2021-02-18
HRP20240584T1 (hr) 2024-07-19
AU2019299358B2 (en) 2026-04-02
ES2976708T3 (es) 2024-08-07
KR20250153311A (ko) 2025-10-24
SG11202012582QA (en) 2021-01-28
SI3818078T1 (sl) 2024-05-31
FI3818078T3 (fi) 2024-05-14
JP7419273B2 (ja) 2024-01-22
JP2021529527A (ja) 2021-11-04
CA3104684A1 (en) 2020-01-09
EP4368699A2 (en) 2024-05-15
IL324666A (en) 2026-01-01
EP3818078A1 (en) 2021-05-12
IL279782A (en) 2021-03-01
PT3818078T (pt) 2024-04-18
IL279782B1 (en) 2026-01-01
BR112020025623A2 (pt) 2021-03-23
DK3818078T3 (da) 2024-05-21
EA202092904A1 (ru) 2021-04-22
JP2026048825A (ja) 2026-03-17

Similar Documents

Publication Publication Date Title
ES2664194T3 (es) Método novedoso para la producción de células diferenciadas
EP4368699A3 (en) Methods of producing recombinant proteins
EA201270213A1 (ru) Способ получения полипептида или вируса, представляющих интерес, в непрерывной клеточной культуре
BR112022011904A2 (pt) Produção de oligossacarídeo sialilado em células hospedeiras
AR111785A2 (es) Método in vitro de producción de eritrocitos
DE60323468D1 (de) Vögelzell-linien und deren verwendung zur herstellung interessanter biologischer substanzen
ECSP22051779A (es) Métodos para mejorar el cultivo celular con proteínas específicas de cada especie o específicas de cada género y las aplicaciones de los mismos
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
DE60314602D1 (de) Verfahren zur isolierung und kulturexpansion mesenchymaler stamm-/vorläuferzellen aus nabelschnurblut sowie verfahren zur differenzierung von aus nabelschnurblut stammenden mesenchymalen stamm-/vorläuferzellen in unterschiedliche mesenchymgewebe
ES2096084T3 (es) Metodo para determinar la presencia de anticuerpos asociados con la diabetes o de anticuerpos dirigidos a celulas de los islotes.
AR053947A1 (es) Celulas huespedes recombinantes y medios para la produccion de etanol
JP7680418B2 (ja) 高密度連続接種の細胞培養方法及びその応用
JP2021529527A5 (cg-RX-API-DMAC7.html)
CN115951057B (zh) 一种迁移体标记物
Nogawa et al. Mechanical aspects of the mesenchymal influence on epithelial branching morphogenesis of mouse salivary gland
JPWO2022019306A5 (cg-RX-API-DMAC7.html)
CN111826285B (zh) 一种单细胞克隆培养方法
CN108865977A (zh) 一种新生大鼠皮肤终隔细胞大量扩增方法及应用
CN103484428A (zh) Cape在体外培养造血干/祖细胞中的用途
BR112017017303B8 (pt) Método para obtenção de clones de células de alta produtividade
CN112175993B (zh) 一种稳定高表达蛋白的单拷贝细胞株的构建方法及其应用
CN116536251B (zh) 一种无饲养层的化学诱导多能干细胞单克隆建株方法
CN104017768B (zh) 细胞体外收集方法及其应用、体外细胞材料及其应用
CN105132353A (zh) 一种获取单克隆细胞的方法
MX2023001270A (es) Proceso de fermentacion industrial para bacillus mediante el uso de recoleccion parcial.